"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

Funds to support ongoing Phase 1 trial of MNA-001 and validation of translational biomarkers for TREM2 function in Alzheimer's Work will inform Phase 2 trials assessing the potential of MNA-001 to ...

Potentially more than 90% of Alzheimer's disease cases would not occur without the contribution of a single gene (APOE), ...

The results of a recent study suggest that people with a weaker or more irregular body clock, also known as circadian rhythm, ...

Reem Hospital has announced the successful completion and database lock of its clinical trial, the TauRx TRx-237-805 study, a ...

One gene called APOE has long been known to increase the risk of Alzheimer’s disease, but without a specific variant most ...

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate ...

A new study found that fixing energy balance in the brain reversed symptoms of advanced Alzheimer’s in mice.  Researchers ...

Routine vaccinations offered to adults may help protect against dementia, recent research has shown.

For over a century, Alzheimer's disease (AD) has been considered irreversible. Consequently, research has focused on disease ...

Finger-prick blood test accurately detects Alzheimer’s biomarkers, enabling at-home collection and broader research ...

Neumora Therapeutics (NMRA) stock jumps as the company posts early-stage trial data for its experimental drug for Alzheimer’s ...